18:34
New research on laser therapy for hair loss. Does it work?
Haircafe
Overview
This video critically examines low-level laser light therapy (LLLT) for hair loss, questioning its efficacy and safety based on recent research. The presenter distinguishes between FDA clearance and approval, highlighting that LLLT devices are cleared, not approved, meaning their effectiveness hasn't undergone rigorous testing. While some new studies show mild positive results, they are often small, short-term, and potentially biased due to manufacturer funding. Concerns are raised about long-term safety, particularly the theoretical risk of cancer due to repeated exposure to laser energy on the scalp, an area prone to skin cancer. Ultimately, the video concludes that LLLT is likely not a worthwhile treatment for most individuals compared to established, FDA-approved therapies.
How was this?
Save this permanently with flashcards, quizzes, and AI chat
Chapters
- Low-level laser light therapy (LLLT) for hair loss is revisited after three years.
- Previous conclusion: LLLT is at best a mild growth stimulant, not a substitute for FDA-approved treatments like finasteride and minoxidil.
- Earlier studies were flawed due to small sample sizes, short follow-ups, and manufacturer bias.
- New research and products have emerged, prompting a re-evaluation.
Understanding the history of research and the presenter's prior skepticism provides context for the new evidence and helps evaluate potential biases.
The presenter mentions linking to previous videos on older research for viewers interested in the historical perspective.
- LLLT devices are FDA cleared, not FDA approved, a crucial difference often misrepresented.
- FDA clearance requires showing similarity to a previously cleared device, not proving efficacy.
- FDA approval involves rigorous Phase 1, 2, and 3 trials with thousands of subjects.
- Manufacturers often use 'FDA approved' misleadingly in marketing and even in published literature.
This distinction is vital for consumers to understand the level of scientific evidence supporting a product's claims and to avoid being misled by marketing.
The HairMax laser comb, the first device cleared by the FDA for hair loss, received 510(k) clearance, not full FDA approval, yet marketing sometimes uses the term 'FDA approved'.
- A double-blind, placebo-controlled study from Korea randomized 60 participants to a real or sham laser helmet.
- The treatment used a 655 nm wavelength for 25 minutes every other day for 16 weeks.
- Results showed significant increases in hair density and thickness in the treatment group compared to placebo.
- The study's dramatic results are noted as an outlier compared to other similar studies.
- Investigators expressed uncertainty about participants adhering to study rules regarding other hair loss treatments.
This study presents positive findings, but its outlier status and methodological concerns warrant caution in interpreting its results.
Hair density increased by 42 hairs/cm² in the laser group versus 1 hair/cm² in the control group; hair thickness increased by 7.5 microns versus thinning by 15 microns in the control.
- A study from India compared laser therapy combined with topical minoxidil against minoxidil alone.
- The laser comb (655 nm) was used twice weekly for 16 weeks.
- A small, statistically insignificant increase in hair growth was observed with the addition of the laser comb.
- Physician and patient evaluations showed no significant difference between the groups.
- This study suggests no added benefit from combining laser therapy with standard minoxidil treatment.
This study provides a contrasting outcome to the first, questioning the utility of laser therapy even as an adjunctive treatment.
The difference in hair density increase between the laser+minoxidil group (14.78%) and the minoxidil-only group (11.43%) was not statistically significant (p=0.45).
- A large study (1,383 subjects) from China used data from an 'i-helmet' app.
- This was a retrospective database study, not a randomized controlled trial, lacking a control group.
- Participants self-evaluated their results, with some dermatologist review.
- The study identified predictors of improvement, such as male gender and number of sessions.
- Interestingly, individuals with rashes or itchy scalps seemed to benefit more, a finding the presenter finds peculiar.
While large, the study's methodology (lack of control, self-reporting) raises significant doubts about the validity of its findings on effectiveness.
The helmet was described as 'moderately effective' in over 50% of users, but this was based on self-assessment without a placebo comparison.
- The long-term safety of LLLT is largely unknown, as most studies are short-term.
- Repeated exposure to laser energy, like UV light, theoretically could cause cell mutations.
- Studies suggest that higher levels of laser exposure can increase the proliferation of cancer cells (e.g., melanoma, epithelial cells).
- The scalp is a common site for skin cancer, making long-term laser application potentially risky.
- The lack of long-term safety data and the FDA clearance status make the long-term risks uncertain.
This chapter introduces a significant potential downside of LLLT that is not addressed by short-term studies or the current FDA clearance process.
A 2009 study showed that higher levels of laser exposure increased melanoma tumor size in mice, while lower levels slightly decreased it.
- LLLT likely has some beneficial effect, but results are inconsistent and long-term data is lacking.
- It is not a substitute for FDA-approved treatments like finasteride or minoxidil.
- The long-term safety profile is not well-established, unlike FDA-approved treatments.
- LLLT might be a temporary option for individuals who cannot use other treatments, but its benefits are likely short-lived.
- It does not appear to offer significant added benefits when used with minoxidil.
This provides a final assessment of LLLT's value, guiding viewers on whether to consider it based on current evidence and potential risks.
The presenter suggests that even for a teenager too young for finasteride, minoxidil is a better and cheaper choice than laser therapy.
Key takeaways
- LLLT devices for hair loss are FDA cleared, not FDA approved, meaning their efficacy and safety have not been rigorously tested through large-scale clinical trials.
- The distinction between FDA clearance and approval is critical for understanding the scientific basis behind a treatment's claims.
- Recent studies on LLLT show mixed results, with some indicating mild benefits but often suffering from methodological flaws like small sample sizes, short durations, and potential bias.
- The long-term safety of repeated LLLT application to the scalp is unknown, raising theoretical concerns about increased cancer risk due to cellular mutation.
- LLLT is unlikely to be a primary or highly effective treatment for hair loss and is generally outclassed by established, FDA-approved therapies like finasteride and minoxidil.
- Adding LLLT to existing treatments like minoxidil does not appear to provide significant additional benefits based on current research.
- Consumers should be wary of marketing that overstates the benefits or misrepresents the regulatory status of LLLT devices.
Key terms
Low-Level Laser Light Therapy (LLLT)FDA ClearanceFDA Approval510(k) Pre-market NotificationAndrogenic AlopeciaDouble-Blind StudyPlacebo ControlSham TreatmentAdjunctive TherapyReal-World Study
Test your understanding
- What is the fundamental difference between FDA clearance and FDA approval, and why is this distinction important for LLLT devices?
- How do the methodological limitations of current LLLT studies (e.g., sample size, duration, bias) impact the reliability of their findings?
- What are the theoretical long-term safety concerns associated with repeated LLLT use on the scalp, particularly regarding cancer risk?
- Based on the presented research, what is the likely efficacy of LLLT as a standalone treatment versus an adjunctive therapy for hair loss?
- Under what specific circumstances, if any, might LLLT be considered a reasonable option for someone experiencing hair loss?